InnoPharma, Inc. announced the launch of acamprosate calcium, 333 mg delayed-release tablets (generic equivalent of Campral(R)). InnoPharma developed the generic formulation of acamprosate delayed-release tablets and entered into an agreement with Glenmark Pharmaceuticals, Inc. pursuant to which Glenmark will sell, market and distribute acamprosate in the United States. Acamprosate calcium is indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation.